Latest Ratios: P/E Ratio -6.0x · EV/EBITDA 17.8x · ROE -24.5%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $5.4B | $5.5B | $8.4B | $11.8B | $11.8B | $15.6B | $19.5B | $17.7B | $12.1B | $11.6B | $7.7B |
| Enterprise Value | $7.7B | $7.8B | $9.8B | $13.5B | $13.3B | $17.1B | $21.7B | $19.4B | $13.9B | $13.5B | $8.2B |
| P/E Ratio → | -6.01 | — | 120.26 | 33.11 | 32.50 | 32.11 | 58.05 | 38.41 | 60.25 | 76.09 | 32.36 |
| P/S Ratio | 2.70 | 2.74 | 2.75 | 3.97 | 4.23 | 5.54 | 7.67 | 6.83 | 4.94 | 5.41 | 4.11 |
| P/B Ratio | 1.74 | 1.75 | 1.96 | 2.66 | 2.94 | 4.15 | 5.83 | 5.95 | 4.76 | 4.78 | 3.59 |
| P/FCF | 21.96 | 22.24 | 16.46 | 28.14 | 44.91 | 26.87 | 56.30 | 52.63 | 33.93 | 33.27 | 21.61 |
| P/OCF | 15.82 | 16.02 | 13.18 | 23.10 | 34.52 | 23.92 | 44.60 | 40.33 | 27.66 | 27.65 | 18.80 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 3.91 | 3.23 | 4.54 | 4.78 | 6.09 | 8.53 | 7.49 | 5.68 | 6.30 | 4.37 |
| EV / EBITDA | 17.81 | 17.97 | 23.14 | 18.04 | 18.28 | 19.76 | 33.29 | 30.31 | 26.14 | 25.64 | 18.68 |
| EV / EBIT | 30.19 | 62.44 | 61.92 | 26.00 | 26.69 | 27.74 | 51.04 | 46.26 | 43.08 | 36.81 | 27.17 |
| EV / FCF | — | 31.74 | 19.33 | 32.20 | 50.77 | 29.49 | 62.63 | 57.70 | 38.98 | 38.76 | 22.99 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.2% | 56.2% | 55.9% | 55.4% | 54.9% | 55.2% | 52.2% | 54.3% | 56.5% | 54.6% | 53.3% |
| Operating Margin | 12.8% | 12.8% | 5.0% | 17.0% | 17.9% | 22.4% | 16.7% | 16.5% | 13.1% | 17.3% | 17.1% |
| Net Profit Margin | -45.4% | -45.4% | 2.3% | 12.0% | 13.0% | 17.3% | 13.2% | 17.8% | 8.2% | 7.1% | 12.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -24.5% | -24.5% | 1.6% | 8.4% | 9.3% | 13.7% | 10.6% | 16.7% | 8.1% | 6.7% | 11.4% |
| ROA | -12.9% | -12.9% | 1.0% | 4.9% | 5.3% | 6.9% | 5.0% | 7.3% | 3.2% | 3.0% | 6.1% |
| ROIC | 3.4% | 3.4% | 1.9% | 6.5% | 6.9% | 8.7% | 6.2% | 7.1% | 5.6% | 8.0% | 8.9% |
| ROCE | 4.0% | 4.0% | 2.3% | 7.6% | 8.0% | 9.8% | 6.8% | 7.5% | 5.6% | 8.1% | 9.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.87 | 0.87 | 0.41 | 0.43 | 0.46 | 0.52 | 0.77 | 0.67 | 0.85 | 0.93 | 0.48 |
| Debt / EBITDA | 6.29 | 6.29 | 4.12 | 2.57 | 2.51 | 2.27 | 3.94 | 3.13 | 4.06 | 4.26 | 2.36 |
| Net Debt / Equity | — | 0.75 | 0.34 | 0.38 | 0.38 | 0.41 | 0.66 | 0.57 | 0.71 | 0.79 | 0.23 |
| Net Debt / EBITDA | 5.38 | 5.38 | 3.44 | 2.28 | 2.11 | 1.76 | 3.37 | 2.67 | 3.39 | 3.63 | 1.12 |
| Debt / FCF | — | 9.50 | 2.88 | 4.06 | 5.86 | 2.62 | 6.33 | 5.07 | 5.05 | 5.49 | 1.38 |
| Interest Coverage | 1.24 | 1.24 | 1.90 | 6.10 | 9.22 | 10.82 | 6.38 | 5.23 | 3.13 | 4.45 | 5.47 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.54 | 2.54 | 2.27 | 2.32 | 2.43 | 2.10 | 2.63 | 2.32 | 2.12 | 2.33 | 2.77 |
| Quick Ratio | 2.01 | 2.01 | 1.34 | 1.29 | 1.43 | 1.40 | 1.68 | 1.47 | 1.39 | 1.51 | 2.03 |
| Cash Ratio | 0.52 | 0.52 | 0.47 | 0.37 | 0.50 | 0.65 | 0.70 | 0.53 | 0.61 | 0.69 | 1.27 |
| Asset Turnover | — | 0.29 | 0.43 | 0.39 | 0.40 | 0.41 | 0.35 | 0.41 | 0.39 | 0.35 | 0.48 |
| Inventory Turnover | 2.16 | 2.16 | 2.24 | 2.12 | 2.18 | 2.64 | 2.36 | 2.49 | 2.49 | 2.46 | 2.76 |
| Days Sales Outstanding | — | 63.30 | 55.04 | 54.42 | 53.47 | 49.83 | 56.84 | 58.88 | 54.61 | 58.82 | 53.15 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 1.1% | 1.1% | 0.8% | 0.5% | 0.5% | 0.4% | 0.3% | 0.4% | 0.5% | 0.5% | 0.8% |
| Payout Ratio | — | — | 91.2% | 17.9% | 17.6% | 13.1% | 18.9% | 13.6% | 31.0% | 40.1% | 24.8% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 0.8% | 3.0% | 3.1% | 3.1% | 1.7% | 2.6% | 1.7% | 1.3% | 3.1% |
| FCF Yield | 4.6% | 4.5% | 6.1% | 3.6% | 2.2% | 3.7% | 1.8% | 1.9% | 2.9% | 3.0% | 4.6% |
| Buyback Yield | 5.6% | 5.5% | 2.4% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 6.7% | 6.6% | 3.1% | 0.5% | 0.6% | 0.4% | 0.3% | 0.5% | 0.5% | 0.5% | 0.8% |
| Shares Outstanding | — | $45M | $47M | $47M | $47M | $47M | $47M | $47M | $47M | $47M | $48M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TFX stock.
Teleflex Incorporated's current P/E ratio is -6.0x. The historical average is 29.5x.
Teleflex Incorporated's current EV/EBITDA is 17.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 14.2x.
Teleflex Incorporated's return on equity (ROE) is -24.5%. The historical average is 10.0%.
Based on historical data, Teleflex Incorporated is trading at a P/E of -6.0x. Compare with industry peers and growth rates for a complete picture.
Teleflex Incorporated's current dividend yield is 1.11%.
Teleflex Incorporated has 56.2% gross margin and 12.8% operating margin. Operating margin between 10-20% is typical for established companies.
Teleflex Incorporated's Debt/EBITDA ratio is 6.3x, indicating high leverage. A ratio above 4x may signal elevated financial risk.
Key Metrics
Top Statement Risk
Impairments and leverage buildup
Metrics are mathematically derived from official filings.
Margin Resilience Amid Revenue Slide
Gross margin expanded to 58.2% in 2026Q2 despite a 27% revenue decline, but operating margin compressed to 10.6%, per reported quarterly data, indicating cost rigidity.
The gross margin improvement from 49.5% in 2025Q3 to 58.2% in 2026Q2 suggests a favorable product mix or cost actions, yet operating margin at 10.6% remains well below the 19.9% seen in 2025Q2. This divergence implies that SG&A and R&D costs are not flexing with revenue, and the reported net margin of 17.9% in 2026Q2 is distorted by non-operating gains, as operating income of $60.3M is only a fraction of prior levels.
Return on Capital Decay
ROIC fell from 2.0% in 2025Q2 to 0.8% in 2026Q2, while ROE swung to 3.4% from negative territory, as reported in financial statements, indicating deteriorating capital efficiency.
The decline in ROIC from 2.0% to 0.8% over the past year reflects both margin compression and a rising capital base, as total debt increased to $2.9B. The negative ROE in 2025Q3 and Q4, at -10.1% and -20.6% respectively, was driven by impairment charges, but the recovery to 3.4% in 2026Q2 is modest and may not signal a sustainable return to prior profitability levels.
Working Capital Stretch
Cash conversion cycle lengthened to 143 days in 2026Q2 from 197 days a year earlier, as DIO dropped to 140 days, per reported figures, suggesting improved inventory management.
The reduction in DIO from 217 days in 2025Q4 to 140 days in 2026Q2 is a positive sign, but DSO remains elevated at 58 days, and DPO at 55 days indicates limited supplier leverage. The overall CCC improvement is partly due to revenue decline, and the volatility in working capital components, as seen in prior cash flow analysis, suggests that efficiency gains may not be sustainable.
Leverage Doubles, Coverage Weakens
Debt-to-equity climbed to 0.99 in 2026Q2 from 0.40 in 2024Q2, while interest coverage fell to 2.61, per reported data, signaling increased financial risk.
The rapid increase in leverage, with total debt reaching $2.9B, has outpaced equity, which declined to $2.9B due to cumulative losses. Interest coverage of 2.61 in 2026Q2 is thin, and the negative coverage in 2025Q3 and Q4 highlights vulnerability to further earnings shocks. The D/EBITDA ratio of 39.3 in 2026Q2 is distorted by depressed EBITDA, but the trend warrants close monitoring.
Liquidity Ratios Mask Cash Drain
Current ratio improved to 2.60 in 2026Q2, but cash fell to $300.2M from $393.3M in 2025Q4, as reported in quarterly statements, suggesting tightening liquidity.
The current ratio appears healthy, but the decline in cash reserves, combined with aggressive buybacks of $245.4M in 2026Q2, indicates that liquidity is being consumed. The quick ratio of 2.12 suggests inventory is not a major liquidity concern, but the reliance on working capital swings for cash flow, as noted in prior analysis, could strain liquidity if revenue continues to decline.
Misapplied P/E Ratio
The trailing P/E of -6.57 is meaningless due to impairment-driven losses; forward P/E of 19.95 better reflects normalized earnings, but EV/EBITDA of 18.96 may overstate value.
The negative trailing P/E is a result of non-cash impairments, not operational deterioration, so investors should focus on forward multiples. However, the forward P/E of 19.95 assumes a recovery in earnings that may not materialize given the revenue decline and cost rigidity. EV/EBITDA of 18.96 is elevated relative to peers like Merit Medical (18.19), but the high D/EBITDA ratio suggests that EBITDA is depressed, making the multiple less reliable. A more appropriate metric would be EV/EBIT or EV/operating cash flow, which better capture the company's earning power.